Ingen internetforbindelse — viser den gemte version af siden.

Novo Nordisk A/S

DEEUR
← Til Screeneren

Novo Nordisk A/S (LSE:0QIU) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

⚠ Forveksl dem ikke: der findes et andet firma med samme eller et meget lignende navn. Det er en separat registrering — tjek ticker, børs og registreringsnummer.

Om Virksomheden

Websted
novonordisk.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hovedkontor
BAGSVAERD DENMARK, Denmark
Administrerende Direktør
Maziar Mike Doustdar
Ansatte
66 700
Udestående Aktier
3.34 mia.
Free Float
3.17 mia.
Markedsværdi
150.93 mia. EUR
Insidere
5.27%
Institutionelle Investorer
33.78%
Branche (SIC)
Pharmaceutical Preparations
Juridisk Form
ZRPO
ISIN
DK0060534915
LEI
549300DAQ1CVT6CXN342
Udbetalingsgrad
50.5%
FCF
59.0 mia. DKK
Udbetaling / FCF
88%
Gæld
143 mia. DKK
2.0 år FCF
Udbyttestreak
24 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.12.2025 (selskabets seneste rapport).
Beskrivelse

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

annonce

Børser og Tickere

BørsTickerValutaPrisType
XETRA XetraNOV primærEUR33.21 +0.00%almindelige aktier
LSE London Stock Exchange0QIU IOBGBP257.55 +1.45%almindelige aktier
US USA StocksNONOF OTCUSD38.84 -1.61%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Pr. År, XETRA:NOV: 1.5636 EUR (2 udb.)

Novo Nordisk A/S (NOV) udbetaler udbytte to gange om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 1.5636 EUR pr. Aktie (betalinger: 2). Det svarer til cirka 4.71% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 01.01.2027. Uafbrudt udbyttehistorik: 24 år.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-08-142026-08-180.5012 EUR1.5/4.7 %halvårligXETRA:NOV
2026-03-27—1.0624 EUR3.2/3.2 %halvårligXETRA:NOV

Største Ejere

EjerAndelAktierRapportdato
VANGUARD STAR FUNDS-Vang…1.38%46.88 mio.2026-07-31
EuroPacific Growth Fund-…1.07%36.2 mio.2026-06-30
VANGUARD TAX-MANAGED FUN…0.92%31.13 mio.2026-06-30
Capital World Growth & I…0.77%26.02 mio.2026-06-30
iShares Trust-iShares Co…0.71%24.13 mio.2026-08-31
Income Fund of America0.52%17.78 mio.2026-07-31
Dodge & Cox Funds-Dodge…0.39%13.1 mio.2026-06-30
Fidelity Concord Street…0.37%12.52 mio.2026-07-31
iShares Trust-iShares MS…0.34%11.48 mio.2026-08-31
Capital Income Builder0.3%10.32 mio.2026-07-31
Cygnus Capital Advisors,…0%78 8002026-06-30
Generali Investments Cee…0%27 3992026-06-30
Pacer Advisors, Inc.0%24 4102026-06-30
Atlas Capital Advisors I…0%5 2182026-06-30
Novo Holdings———
Novo Nordisk Foundation———